ObjectiveTo explore the clinical effects of entecavir combined with Fuzheng Huayu tablets in the treatment of chronic hepatitis B infection-induced liver cirrhosis. MethodsA total of 100 patients with chronic hepatitis B infection-induced liver cirrhosis who were admitted to our hospital from March 2017 to March 2020 were selected as the observation objects. The random number method was used to divide the patients into control group and combined group, with 50 cases in each group. The patients in the control group received conventional symptomatic treatment and entecavir dispersible tablets, based on which the combination group administrated Fuzheng Huayu tablets as adjuvant therapy. The two groups were treated for 24 weeks. The clinical efficacy and the pre- and post-treatment levels of peripheral blood hyaluronidase (HA), laminin (LN), procollagen type Ⅲ (PC Ⅲ) and collagen type Ⅳ (Ⅳ-C), as well as the negative rate of hepatitis B virus and the occurrence of adverse drug reactions were compared between the two groups. ResultsThe clinical efficacy of the combined group was significantly superior to that of the control group (P＜0.05). After 24 weeks of treatment, the levels of HA, LN, PCⅢ, and Ⅳ-C significantly decreased in both groups, and the combination group yielded lower levels mentioned above as compared with the control group, with statistically significant differences (P＜0.05). There were no statistically significant differences in hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), HBV-DNA conversion rate and the incidence of adverse reactions between the two groups (P＞0.05). ConclusionEntecavir combined with Fuzheng Huayu tablets has a definite clinical effect in the treatment of chronic hepatitis B infection-induced liver cirrhosis. It can effectively improve liver fibrosis condition in patients, whereas it does not increase adverse reactions.

无